Evidence map›Paper›PMID 25737829›Full record

ArticleOsong public health and research perspectives2015

Evaluation of Mycobacterium tuberculosis Early Secreted Antigenic Target 6 Recombinant Protein as a Diagnostic Marker in Skin Test.

Jale Moradi, Nader Mosavari, Mahmoud Ebrahimi, Reza Arefpajohi, Majid Tebianian

Open access · diamondAbstract read
In one paragraph

Article in Osong public health and research perspectives, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Production of MPT-64 recombinant protein from virulent strain ofIranian journal of veterinary research · 2018
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Jale MoradiDepartment of TB, Razi Vaccine and Serum Research Institute, Karaj, Iran.
Nader MosavariDepartment of TB, Razi Vaccine and Serum Research Institute, Karaj, Iran.
Mahmoud EbrahimiDepartment of TB, Razi Vaccine and Serum Research Institute, Karaj, Iran.
Reza ArefpajohiDepartment of TB, Razi Vaccine and Serum Research Institute, Karaj, Iran.
Majid TebianianDepartment of TB, Razi Vaccine and Serum Research Institute, Karaj, Iran.
Razi Vaccine and Serum Research Institute · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTuberculosis (TB) is the leading infectious disease in the developing world. Delayed-type hypersensitivity skin test diagnoses TB using tuberculin purified protein derivative (PPD), but this test is incapable of distinguishing Mycobacterium tuberculosis (MTB) infection from bacillus Calmette-Guérin (BCG) vaccination or an infection caused by nontuberculous mycobacteria (NTM). This study was performed to evaluate the use of recombinant early secretory antigenic target 6 (rESAT-6), a secretory protein found only in MTB, Mycobacterium bovis, and few other mycobacterial species, as a skin marker for MTB in guinea pigs.

methodsWe prepared recombinant MTB ESAT-6 and evaluated its use as a specific antigen for MTB in guinea pigs.

resultsOur results show that the purified MTB rESAT-6 antigen is capable of inducing a positive reaction only in guinea pigs sensitized to MTB. No such reaction was observed in the animals sensitized to M. bovis, BCG vaccination, or NTM (Mycobacterium avium).

conclusionOur study results confirm that the ESAT-6 antigen is more specific to MTB infection than PPD and could be used in more specific skin tests for detection of MTB in large animals and in humans.

Indexed as

early secretory antigenic target 6Mycobacterium tuberculosispQE60 vectorpurified protein derivativerecombinant early secretory antigenic target 6

Identifiers

PMID25737829
PMCPMC4346597
OpenAlexW2002834956

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.